Adaptimmune Therapeutics Plc Stock Price, News & Analysis

Adaptimmune Therapeutics (Nasdaq: ADAP) announced preclinical data on its HiT targeting mesothelin at the ASGCT meeting. The HLA-independent TCR technology showed promising results, inducing complete tumor regression in a mouse model and outperforming a TRuC comparator. Notably, human T-cells expressing the HiT effectively killed mesothelin-expressing tumor cells, independent of CD8. Unlike the TRuC construct, the HiT was not neutralized by soluble mesothelin, highlighting its potential advantages for future cancer therapies.

Adaptimmune Therapeutics plc (Nasdaq: ADAP) announced updates on May 6, 2021, highlighting progress in its clinical trials and financial performance for Q1 2021. Key developments include the initial data presentation from the SPEARHEAD-1 trial at ASCO, increased enrollment in the SURPASS and ADP-A2AFP trials, and a financial report showing $0.4 million in revenue. R&D expenses rose to $24.5 million. The company confirmed it has sufficient liquidity to fund operations into early 2023. The second target has been nominated under the co-development agreement with Astellas.

Adaptimmune Therapeutics (Nasdaq:ADAP) announced the upcoming presentation of initial preclinical data on its HLA Independent TCR (HiT) targeting mesothelin, co-developed with Astellas, at the ASGCT meeting. This will occur on May 11, 2021, during the Cancer - Immunotherapy session, with abstract #641 published online. Adaptimmune focuses on cell therapies for cancer, utilizing its SPEAR T-cell platform to combat various solid tumors. The release contains forward-looking statements, indicating potential risks related to product development and regulatory processes.

Adaptimmune Therapeutics (Nasdaq:ADAP) will report its Q1 financial results and business update on May 6, 2021, before market opening. The company specializes in cancer immunotherapy using its SPEAR T-cell platform. Following the results announcement, a live teleconference will take place at 9:00 a.m. EDT. Investors can access the webcast on Adaptimmune's corporate site. The release highlights the company’s focus on advancing TCR therapeutic candidates while noting potential risks and uncertainties inherent in product development and regulatory processes.

Adaptimmune Therapeutics (ADAP) has reported significant advancements in its cell therapy strategies, aiming for a market presence by 2025 through its '2-2-5-2' plan. In 2020, the company achieved compelling results in treating synovial sarcoma and completed enrollment in the SPEARHEAD-1 trial, with plans for a Biologics License Application in 2022 for ADP-A2M4. Additionally, the company will initiate a Phase 2 trial (SURPASS-2) for esophageal and esophagogastric junction cancers. Financially, Adaptimmune ended 2020 with $368.2 million in total liquidity, supporting operations into early 2023.

Adaptimmune Therapeutics (Nasdaq:ADAP) is set to announce its financial results and provide business updates for Q4 and the year ending December 31, 2020, before market open on February 25, 2021. A live teleconference and webcast will follow at 8:00 a.m. EST. Adaptimmune specializes in developing cancer immunotherapy using its unique SPEAR^® T-cell platform designed to target various solid tumors. The press release includes forward-looking statements, highlighting risks associated with product development and clinical trials.

Adaptimmune Therapeutics (ADAP) announced its ongoing enrollment in the SPEARHEAD-1 trial, targeting ADP-A2M4 for synovial sarcoma. The company is set to initiate a trial for ADP-A2M4CD8 in gastroesophageal cancers in the first half of 2021. The MAGE-A4 target shows strong efficacy potential across multiple solid tumors. Adaptimmune aims to introduce five new autologous products and two allogeneic products by 2024. Financial guidance is updated, indicating funding through early 2023. A Virtual Investor Day is scheduled, showcasing strategic visions and growth plans.

Adaptimmune Therapeutics (Nasdaq: ADAP) presented positive data from the Phase 1 ADP-A2M4 trial for synovial sarcoma at the CTOS annual meeting. The trial showed a 28-week median duration of response and a 94% disease control rate among 16 patients. The company aims to complete recruitment for the pivotal SPEARHEAD-1 trial by Q1 2021, with a goal to commercialize ADP-A2M4 in 2022. Additional trials for gastroesophageal cancers are planned for H1 2021.

Adaptimmune Therapeutics, a leader in cancer cell therapy, will host a virtual Investor Day on November 20, 2020. The event, set for 8 AM EST / 1 PM GMT, aims to highlight the market potential of its SPEAR T-cell portfolio and discuss its early-stage pipeline beyond current autologous TCR T-cell products. Presentations will be made by the Senior Leadership Team and Dr. Dejka Araujo from MD Anderson Cancer Center. Interested parties can register here.